CliffBio
small molecule

ATAZANAVIR SULFATE

ATAZANAVIR SULFATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameATAZANAVIR SULFATE
Active ingredientATAZANAVIR SULFATE
StrengthEQ 150MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ATAZANAVIR SULFATE patent cliff — loss of exclusivity — | CliffBio